Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | CYP8B1 | Q9UNU6 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 3/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | MELK | Q14680 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071738 | 0.85 | ABCB1 (0.49) | ENPP1ABCB1ABCC1ABCG2CYP8B1 | |
| SCHEMBL4072482 | 0.82 | HSD17B10 (0.39) | SUV39H2 | |
| SCHEMBL4066842 | 0.80 | ENPP1 (0.46) | ENPP1PDE10ASUV39H2ABCB1ABCC1 | |
| SCHEMBL4073225 | 0.80 | SUV39H2 (0.47) | ENPP1SUV39H2ACHE | |
| SCHEMBL30163242 | 0.79 | HRH3 (0.45) | — | |
| SCHEMBL5751891 | 0.72 | ENPP1 (0.42) | ENPP1SUV39H2PTPN11MELK | |
| SCHEMBL4063525 | 0.71 | KCNH2 (0.44) | — | |
| SCHEMBL4068347 | 0.69 | POLB (0.43) | — | |
| SCHEMBL4066233 | 0.67 | NCF1 (0.62) | ENPP1 | |
| SCHEMBL4071728 | 0.67 | ALDH1A1 (0.48) | CES2MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605938-B1 | Antibacterial derivatives of napthydrin and quinoline | GLAXO GROUP LTD (GB) | 2009-02-11 | — | — | EP | disclosed |
| US-20060189601-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189601-A1 | Antibacterial agents | NQO2, NRDC, IFNG | ENPP1 577/4885PDE10A 4240/4885SUV39H2 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.